EUVIMEDOpdag EUVIMED
KohortenstudieOpen access · CC BY-NC 3.0

Neoadjuvant Nivolumab–Ipilimumab versus Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: A Single-Institution, Propensity-Weighted Cohort Study

Li-Hua Huang iD, Min-Che Tung, Wei-Chun Weng, Chao-Yu Hsu, Yen-Chuan Ou, Chi-Chien Lin

Cancer Management and Research · 2026-11 · Volume 18 · 1-13

DOI: 10.2147/cmar.s642002 ↗

At a glance

Kohortenstudie in Cancer Management and Research, 2026-11. Written by Li-Hua Huang and 5 co-authors. Institution: Department of Urology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan. The full text is freely available (open access, CC BY-NC 3.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Neoadjuvant chemotherapy (NAC) is standard for muscle-invasive bladder cancer (MIBC), yet many patients are platinum-ineligible. We compared outcomes of neoadjuvant nivolumab plus ipilimumab versus platinum-based NAC.

Methods

This single-institution comparative cohort study compared a prospective immune checkpoint inhibitor (ICI) cohort (n=11) receiving nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) against a retrospective platinum-based NAC cohort (n=30). Propensity score-based overlap weighting was used to reduce measured confounding. Main outcomes included pathologic complete response (pCR), downstaging (

Subjects

Author keywords

ICIMIBCNACimmune checkpoint inhibitoripilimumabmuscle-invasive bladder cancerneoadjuvant chemotherapynivolumabpropensity score weighting

Authors and institutions

  • Department of Urology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan.
  • Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
  • Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
  • Department of Nursing, Jenteh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan.
  • Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.

ORCID profiles: Li-Hua Huang

Cite

APA

Huang, L. H., Tung, M. C., Weng, W. C., Hsu, C. Y., Ou, Y. C., & Lin, C. C. (2026). Neoadjuvant Nivolumab–Ipilimumab versus Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: A Single-Institution, Propensity-Weighted Cohort Study. Cancer Management and Research, Volume 18, 1-13. https://doi.org/10.2147/cmar.s642002

Vancouver

Huang LH, Tung MC, Weng WC, Hsu CY, Ou YC, Lin CC. Neoadjuvant Nivolumab–Ipilimumab versus Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: A Single-Institution, Propensity-Weighted Cohort Study. Cancer Management and Research. 2026;Volume 18:1-13. doi:10.2147/cmar.s642002

BibTeX
@article{Huang2026,
  author = {Huang, Li-Hua and Tung, Min-Che and Weng, Wei-Chun and Hsu, Chao-Yu and Ou, Yen-Chuan and Lin, Chi-Chien},
  title = {Neoadjuvant Nivolumab–Ipilimumab versus Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: A Single-Institution, Propensity-Weighted Cohort Study},
  journal = {Cancer Management and Research},
  year = {2026},
  volume = {Volume 18},
  pages = {1--13},
  doi = {10.2147/cmar.s642002}
}
Start for free →